Merck's acquisition of Sigma-Aldrich close to completion
Twelve months after pharmaceutical company Merck announced its intention to buy US life science company Sigma-Aldrich, steady progress has been made towards closing the deal.
On 22 September 2014, Merck revealed its agreement with Sigma-Aldrich to purchase the latter for US$17 billion — US$140 cash per share — establishing itself as one of the leading players in the US$130 billion global life science industry. The merged company will be led by Merck Millipore CEO Udit Batra.
On 11 August 2015, Sigma-Aldrich and Merck announced they had obtained all necessary antitrust approvals, with the approval of the European Commission (EC) being conditional upon the sale of parts of Sigma-Aldrich’s solvents and inorganics business in Europe. Negotiations with potential buyers are now in the final stage.
Once a binding agreement has been signed, the EC must approve the buyer before Merck can complete the Sigma-Aldrich acquisition. Completion is expected within the next two months.
Optics11 Life appoints Jacquelien ten Dam as CEO
Optics11 Life plans to accelerate its commercial growth in key markets while building strategic...
Epilepsy pioneer elected President of Aust Academy of Science
Laureate Professor Sam Berkovic — one of the world's most respected neurologists...
CSIRO announces 300+ job cuts as part of restructure
CSIRO will need to reduce roles in its Research Units by 300–350 full-time equivalent staff...
